Abstract
This book examines how innovative pharmaceuticals have been regulated in the US and the European Union (EU) since 1980 — a period which we refer to as the ‘neo-liberal era’. Regarding the EU, our principal focus is on the period since 1995 because that is when a supranational EU regulatory agency and system became fully established with specific responsibilities for regulating innovative pharmaceuticals. Like many other writers, we refer to the post-1980 era in the US and western Europe as ‘neo-liberal’ because it was, and remains, a period in which the political project of minimizing state intervention, subjecting the state to competitive tests of ‘the market’, and elevating individual consumer choice above the state as a form of collective decision-making, all came to the fore. This has involved the ‘liberalization’ of markets, that is, relaxation of government regulations and controls believed to hamper business activity and the socio-economic signals of consumer demand (Fisher 2009).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Copyright information
© 2013 Courtney Davis and John Abraham
About this chapter
Cite this chapter
Davis, C., Abraham, J. (2013). Putting Pharmaceutical Regulation to the Test: From Historical Description to a Social Science for Public Health. In: Unhealthy Pharmaceutical Regulation. Health, Technology and Society. Palgrave Macmillan, London. https://doi.org/10.1057/9781137349477_2
Download citation
DOI: https://doi.org/10.1057/9781137349477_2
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-28417-7
Online ISBN: 978-1-137-34947-7
eBook Packages: Palgrave Social Sciences CollectionSocial Sciences (R0)